📰 Imux News
Page 3 - Imux News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Imux. Real-time updates on events, politics, business and more.
April 24, 2023
Immunic, Inc. (NASDAQ:IMUX – Get Rating) has received a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The […]
April 24, 2023
Immunic, Inc. (NASDAQ:IMUX – Get Rating) has been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The […]
March 30, 2023
Shares of Immunic, Inc. (NASDAQ:IMUX – Get Rating) have been assigned an average rating of “Moderate Buy” from the six research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on […]
June 6, 2022
Immunic, Inc. (NASDAQ:IMUX – Get Rating) CFO Glenn Whaley bought 3,500 shares of the company’s stock in a transaction dated Friday, June 3rd. The stock was acquired at an average price of $3.04 per share, for a total transaction of $10,640.00. Following the acquisition, the chief financial officer now directly owns 12,568 shares in the […]
June 6, 2022
Immunic, Inc. (NASDAQ:IMUX – Get Rating) CEO Daniel Vitt purchased 5,000 shares of Immunic stock in a transaction on Friday, June 3rd. The stock was bought at an average price of $3.10 per share, for a total transaction of $15,500.00. Following the completion of the acquisition, the chief executive officer now owns 368,877 shares in […]
June 3, 2022
Shares of Immunic, Inc. (NASDAQ:IMUX – Get Rating) have been assigned a consensus rating of “Hold” from the six analysts that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation and three have given a buy recommendation to the company. The average 1-year price objective among brokerages that […]
May 13, 2022
Wall Street brokerages expect Immunic, Inc. (NASDAQ:IMUX – Get Rating) to post earnings per share of ($0.76) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Immunic’s earnings, with estimates ranging from ($0.93) to ($0.58). Immunic posted earnings per share of ($0.82) in the same quarter last year, which […]
May 13, 2022
Immunic, Inc. (NASDAQ:IMUX – Get Rating) – Wedbush raised their Q2 2022 earnings estimates for shares of Immunic in a report issued on Tuesday, May 10th. Wedbush analyst L. Moussatos now anticipates that the company will earn ($0.69) per share for the quarter, up from their prior forecast of ($0.77). Wedbush has a “Outperform” rating […]
April 3, 2022
Shares of Immunic, Inc. (NASDAQ:IMUX – Get Rating) have been assigned an average rating of “Buy” from the six analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The […]
April 2, 2022
StockNews.com initiated coverage on shares of Immunic (NASDAQ:IMUX – Get Rating) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the stock. Other analysts have also recently issued research reports about the stock. Wedbush reiterated a “buy” rating and issued a $61.00 price objective on shares of Immunic […]